Lexicon Pharma (LXRX) Tops Q2 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Lexicon Pharmaceuticals Reports Second Quarter 2017 Financial Results And Provides A Business Update
August 1, 2017 7:00 AM EDTTHE WOODLANDS, Texas, Aug. 1, 2017 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended June 30, 2017 and provided an overview of key milestones for the company's commercial product, XERMELO®, and its pipeline drug candidates.
"I am extremely pleased with our performance in the first full quarter of the XERMELO launch as we continue to make significant progress in growing our prescriber base and providing access to XERMELO. This momentum, along with... More
